GlobeImmune plans to use the placement of convertible notes and warrants for general corporate purposes, officials for the privately held company said in the announcement.
Officials for GlobeImmune could not be reached for additional comment.
GlobeImmune, which last year shelved plans for an initial public offering, has several drug programs in clinical studies including Tarmogen product candidates for chronic hepatitis B and a program for patients with thyroid cancer.
(c)2014 the Daily Camera (Boulder, Colo.)
Visit the Daily Camera (Boulder, Colo.) at www.dailycamera.com
Distributed by MCT Information Services